Qiming Venture Partners Weekly | Portfolio Company Funding and Updates Roundup Vol. 36, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Funding News
01/
Qiming Venture Partners Solely Leads Makera's Pre-A Round
Ushering in a New Era of Accessible Precision CNC Tools
Makera, a Chinese consumer-grade CNC (Computer Numerical Control) equipment innovator, recently announced the completion of a tens-of-millions-of-RMB Pre-A funding round, led exclusively by Qiming Venture Partners.
The proceeds will primarily fund core technology R&D iterations, production capacity expansion, and global market channel development. This financing not only signals strong VC recognition of the consumer-grade CNC track, but also foreshadows Makera's imminent opening of a new chapter in democratizing precision CNC tools.
Founded in 2019, Makera is a leading Chinese consumer-grade CNC equipment company dedicated to providing intelligent, user-friendly precision CNC tools for global makers, SMEs, and educational institutions.
Taiyi Ye, Partner at Qiming Venture Partners, commented: "Makera is the world's first desktop CNC equipment brand built around dramatically lowering the barrier to entry for users, and it's currently recognized by professional users as the best product in the industry — from its many innovative hardware designs to its self-developed zero-threshold CAM software. Makera will soon launch its entry-level model, the Makera Z1 (which won Best in Content Creation at IFA 2025), and as its AIGC-powered user community Makerables continues to mature, we believe Makera's desktop CNC devices can enter households just as 3D printers have, allowing more makers and even ordinary consumers to easily experience the extreme precision that CNC machining brings to working with wood, metal, and other materials."
02/
Future Intelligent Closes Hundreds-of-Millions RMB Series A
Qiming Venture Partners Increases Its Stake
Future Intelligent, a leading Chinese AI hardware company, has officially announced the completion of a hundreds-of-millions-of-RMB Series A round, with Qiming Venture Partners increasing its stake through oversubscription. This marks the company's third funding round this year, following its Pre-A and Pre-A+ rounds in January and April respectively, further expanding its cumulative funding scale. The proceeds will be directed toward three priorities: continuing to enrich its AI office hardware product matrix, accelerating the development and marketing of its overseas proprietary brand viaim, and increasing investment in frontier technologies such as AI Agents.
Shiyu Wang, Partner at Qiming Venture Partners, said: "Our continued investment in Future Intelligent is based on the team's deep vertical-scene productization capabilities, proven commercial efficiency, and forward-looking vision for building an AI-powered office ecosystem. This elevated thinking — from intelligent hardware to office ecosystem — demonstrates the team's profound grasp of technology trends and strategic foresight. We look forward to Future Intelligent continuously breaking new ground and growing into a world-leading intelligent office platform."
03/
Thorough Future Completes A++ Round
Pioneering a New Chapter in Global Smart Pathology
Thorough Future, a Qiming Venture Partners portfolio company, recently announced the successful completion of its A++ funding round. This underscores Thorough Future's deep strength in clinical applications of pathology foundation models and its outstanding contributions to digital-intelligent transformation, marking another solid step in advancing global digital-intelligent pathology. Qiming Venture Partners led the Series A round and continued investing in the A+ round.
The proceeds will primarily advance the clinical application and promotion of Thorough Future's brain pathology foundation model, and accelerate the global deployment of digital-intelligent pathology departments. Thorough Future plans to deepen cooperation with top domestic and international medical and research institutions, actively undertake more forward-looking and innovative clinical trials and research projects, continuously optimize and refine its products and services to meet the needs of patients and medical institutions across different regions worldwide. Meanwhile, the company will increase investment in talent development and technology R&D, attract more industry elites, enhance its core competitiveness, and provide global patients with more precise, efficient, and personalized medical services.
Major Partnerships
01/
UBTECH Signs RMB 30 Million Humanoid Robot Purchase Contract
Total Order Value Nears RMB 430 Million
UQI Youqi, the smart logistics subsidiary of UBTECH (09880.HK), a Qiming Venture Partners portfolio company, has formally signed a procurement contract with Tianqi Automation Engineering Co., Ltd. ("Tianqi Lithium"). Tianqi Lithium will purchase UBTECH's Walker S series industrial humanoid robots with a total value of RMB 30 million, to be delivered by December 31, 2025.
To date, UBTECH's Walker series industrial humanoid robots have secured contracts totaling nearly RMB 430 million (including nearly RMB 50 million in humanoid robot orders already delivered in the first half of this year, excluding orders for the full-size research and education humanoid robot Tiangong Xingzhe). In September, UBTECH secured a RMB 250 million procurement contract for embodied intelligence humanoid robot products and solutions from a well-known Chinese enterprise — the largest contract in the global humanoid robot sector to date.
02/
Unisound Signs Strategic Cooperation Agreement with KUPAS
Unisound (09678.HK), a Qiming Venture Partners portfolio company, has formally signed a strategic cooperation agreement with KUPAS. Under the agreement, both parties will pursue mutual development goals, adhering to principles of diverse co-construction, complementary mutual promotion, cross-boundary integration, and competitive cooperation, giving full play to their respective strengths to comprehensively collaborate on technology, markets, and services, and striving to enhance their core competitiveness and sustainable development capabilities in their respective fields.
This strategic cooperation will focus on three directions: first, jointly implementing the "AI+" action initiative and deepening technical synergy in corpus and model application areas; second, leveraging Unisound's industrial deployment advantages to jointly build high-quality industry datasets and establish a close and stable corpus data cooperation system; third, actively fulfilling corporate social responsibility by jointly promoting the prosperity of the large model industry ecosystem and accelerating the construction of open-source datasets.
03/
Hesai Technology Announces Continued Core Strategic Supplier Partnership with Xiaomi Auto for 2026–2027
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI, 02525.HK) announced that it will continue deepening its partnership with Xiaomi Auto from 2026 to 2027, maintaining its position as a core strategic supplier to provide ongoing support and services.
Since Xiaomi Auto's launch, Hesai Technology has been its exclusive lidar partner, continuously powering the rollout of the SU7 and YU7 models. The two parties' deep collaboration has not only advanced the commercial deployment of intelligent driving technology but also delivered safer, smarter mobility experiences for consumers.
Through sustained technological breakthroughs and commercial execution, Hesai Technology has steadily grown into a global leader in the lidar industry. Lidar provides critical 3D environmental perception for smart vehicles, autonomous driving, and robotics — serving as the "eyes of the robot" and an "invisible airbag" for automobiles. Through independent innovation, Hesai has successfully driven lidar technology into the mass market, transforming what was once a prohibitively expensive technology into a core force for global vehicle safety, protecting every person's journey.
04/
DeepWay Deepformal Signs Distribution Agreement with Omani Partner
Recently, Qiming Venture Partners portfolio company DeepWay Deepformal formally signed a dealer cooperation agreement with a core partner in Oman. This partnership follows the company's UAE signing and represents another strategic move in the Middle East market. With the UAE and Oman forming a "north-south呼应" market pattern, DeepWay Deepformal will unlock stronger synergies across core Middle Eastern regions, accelerating the development and extension of its marketing and service network.
DeepWay Deepformal's intelligent new-energy heavy-duty trucks, with core advantages in long-range endurance, high-temperature resistance, and low energy consumption, will effectively meet Oman's operational demands in high-temperature desert environments and complex transport conditions. Additionally, these trucks come fully equipped with the "Tianji·Suixing" combined assisted driving system, the "Tianji·Yanxing" intelligent platooning system, and the "Shenxiang·Tianshu" intelligent connected vehicle platform, providing customers with integrated intelligent solutions covering the full transport workflow.
05/
Gan & Lee Pharmaceuticals Signs Technology Transfer and Supply Agreement with Brazilian Public Laboratory and Biopharma Company
Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) recently partnered with Brazilian public laboratory Fiocruz and local biopharma company Biomm to formally sign a 10-year Technology Transfer and Supply Agreement, marking the official launch of Brazil's "Partnership for Productive Development" program collaboration. Simultaneously, Gan & Lee and Biomm signed a Supply Framework Agreement with cumulative orders over ten years totaling no less than RMB 3 billion.
Under this collaboration, the three parties will form a closed loop of "technology export — localized production — long-term procurement." With over two decades of deep expertise in insulin, Gan & Lee provides full technical enablement for localized Brazilian production through internationally leading R&D, manufacturing processes, and quality control systems. Biomm leverages its deep understanding of local regulations, healthcare systems, and market demands to ensure rapid, compliant product rollout. Fiocruz combines dual roles as both "technology recipient" and "end purchaser," committing to sustained procurement at established prices and volumes over the next decade. Through tripartite collaboration, this will effectively improve the accessibility and affordability of high-quality insulin in Brazil.
R&D Progress
01/
Zai Lab Partner Announces FDA Breakthrough Therapy Designation for Povetacicept
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) partner Vertex announced that povetacicept has been granted Breakthrough Therapy Designation by the FDA for the treatment of IgA nephropathy. If interim analysis data at 36 weeks meets prespecified efficacy endpoints, povetacicept could potentially seek accelerated approval in the United States in the first half of 2026.
Povetacicept is currently being evaluated in the RAINlER study, a global Phase 3 clinical trial in patients with IgA nephropathy. The study will conduct a prespecified interim analysis (IA) assessing urine protein-to-creatinine ratio (UPCR) in the povetacicept arm versus placebo in a defined number of patients who have completed 36 weeks of treatment. The IA cohort has now completed full enrollment.
02/
Ark Bio Publishes APL-1702 International Multicenter Phase 3 Clinical Trial Data in Cell Press Journal
Recently, Qiming Venture Partners portfolio company Ark Bio (688176.SH) announced that results from the international multicenter Phase 3 clinical trial of its product APL-1702 for the treatment of high-grade squamous intraepithelial lesion (HSIL) have been published online in Med, a journal under Cell Press. Founded by Cell Press, Med is the publisher's flagship medical journal following Cell and Chem, ranked Q1 in Journal Citation Reports (JCR) and dual first-tier in the Chinese Academy of Sciences journal classification.
This study aimed to evaluate the efficacy and safety of APL-1702 for cervical HSIL, with Academician Jinghe Lang of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, serving as principal investigator. A total of 402 eligible patients from China, Germany, the Netherlands, and other countries and regions were randomized into the study. Completed statistical analysis results show that the study achieved its primary efficacy endpoint with a favorable safety profile.
03/
SceneRay Deep Brain Stimulator Passes NMPA Innovative Medical Device Review
Recently, an implantable deep brain stimulator developed by Qiming Venture Partners portfolio company SceneRay for the treatment of refractory obsessive-compulsive disorder formally passed review by the National Medical Products Administration (NMPA) and entered the innovative medical device "green channel." This designation recognizes the product's significant innovation and clinical value, granting it priority guidance during the registration and approval process, with the potential to benefit patients suffering from refractory obsessive-compulsive disorder at the earliest opportunity.
SceneRay's deep brain stimulator, which received innovative review approval, represents a breakthrough therapy based on brain-computer interface DBS technology. Brain-computer interface DBS is a minimally invasive, reversible, and adjustable neural modulation technique that improves symptoms by implanting electrodes at specific brain targets to deliver electrical pulses that regulate dysfunctional neural circuits.
Corporate Development
Veteran Tumor Immunotherapy Expert Dr. Mark Selby Officially Joins Ze'an Biopharmaceutical
Qiming Venture Partners portfolio company Ze'an Biopharmaceutical announced that Dr. Mark Selby, a renowned veteran expert in tumor immunotherapy, has officially joined the company as Vice President and Head of Research.
Dr. Selby has dedicated his career to tumor immunology and immunotherapy. An accomplished scientist with over 25 years of experience in immunological drug development, he previously served as Senior Director at Bristol-Myers Squibb, where he led teams focused on discovering and validating novel targets related to immunosuppression in the tumor immune microenvironment and advancing fully human antibody preclinical development. He spearheaded research on anti-PD-1, anti-PD-L1, anti-PD-1 + anti-CTLA-4, anti-LAG-3, and anti-GITR antibody therapies, with multiple antibodies gaining regulatory approval and benefiting cancer patients worldwide.
Product Launches
01/
Shukun Technology's Breast Lesion Ultrasound Image-Assisted Detection Software Receives NMPA Class III Certification
Shukun Technology, a Qiming Venture Partners portfolio company, recently announced that its self-developed breast lesion ultrasound image-assisted detection software has officially received Class III medical device registration approval from China's National Medical Products Administration (NMPA). This approval brings Shukun Technology's total number of NMPA Class III certifications to 19.
A major breakthrough for Shukun Technology's "Digital Human" technology platform in the ultrasound modality, this product features an industry-first core technology matrix that enables real-time parsing of ultrasound scanning video streams and enhanced visualization of lesion information. Its key innovation lies in seamless integration into physicians' existing workflows — enabling immediate lesion detection without additional operations or the distraction of a "second screen." This achieves the goal of true clinical usability, effectively addressing persistent challenges in traditional ultrasound diagnosis such as high miss rates and inconsistent efficiency.
02/
Infervision's Fracture X-Ray Image-Assisted Triage Software Receives NMPA Class III Certification
Infervision, a Qiming Venture Partners portfolio company, recently announced that its self-developed fracture X-ray image-assisted triage software has officially received Class III medical device registration approval from China's National Medical Products Administration (NMPA).
The product provides triage prompts for suspected fracture cases affecting the radius and ulna, hand, wrist, ankle, tibia and fibula, foot, humerus, femur, and ribs in both adult and pediatric patients, assisting physicians in rapid assessment. This approval marks another significant breakthrough for Infervision in orthopedic AI while completing the company's product matrix for grassroots X-ray scenarios.
Technology & Capabilities
01/
WeRide Enters Ras Al Khaimah, UAE; Robotaxi and Robobus Begin Trial Operations
WeRide (NASDAQ: WRD), a Qiming Venture Partners portfolio company, recently announced a partnership with RAKTA (Ras Al Khaimah Transport Authority), the transportation authority of Ras Al Khaimah (one of the seven emirates of the UAE), to officially launch trial operations of WeRide Robotaxi GXR and WeRide Robobus in the emirate. As the sole selected partner for Ras Al Khaimah's smart transportation strategy, WeRide achieved its first deployment in the emirate — a milestone that marks the formal integration of the company's autonomous vehicles into the local public transportation system and paves the way for broader commercial application of WeRide's autonomous products across the UAE.
To further deepen the collaboration, WeRide and RAKTA signed a Memorandum of Understanding (MoU) covering the provision of advanced autonomous driving technology solutions, operational support, and training to ensure safe and efficient deployment of autonomous vehicles in Ras Al Khaimah. This memorandum lays the groundwork for broader commercial rollout of WeRide autonomous vehicles within the emirate's transportation network.
02/
Zhipu AI Announces GLM-4.6 Earns Dual Recognition for Performance and Reputation
Zhipu AI, a Qiming Venture Partners portfolio company, recently announced that GLM-4.6 has earned dual global recognition for performance (rankings) and reputation based on its SOTA (State-of-The-Art) Agentic Coding capabilities — including ranking #1 globally on Hugging Face Trending; placing first among open-source models and fourth globally on LMArena, tied with Qwen Max Preview (closed-source) for top ranking in China; and reaching #1 on OpenRouter, the global large model API marketplace. In an official evaluation, Cline noted: "We analyzed millions of diff edits from Cline users. GLM-4.6 achieved a success rate of 94.9%, compared to Claude 4.5's 96.2%."
As the latest version in the GLM series, GLM-4.6 delivers comprehensive improvements across real-world programming, long-context processing, reasoning capabilities, information retrieval, writing ability, and agent applications. The model's Agentic Coding capabilities rival Claude Sonnet 4, achieving best-in-class results in China; its reasoning, information search, writing, and agent application capabilities have all been substantially enhanced; and with optimization for domestic chips, operational efficiency has been significantly improved.
03/
Tashi Zhihang Releases WIYH, the World's First Scalable Real-World Embodied Multimodal Dataset
Tashi Zhihang, a Qiming Venture Partners portfolio company, recently announced the release of World In Your Hands (hereinafter "WIYH Dataset"), the world's first large-scale real-world embodied VLTA (Vision-Language-Tactile-Action) multimodal dataset, with plans to open it to the industry in December 2025. This achievement marks the formal establishment of Tashi Zhihang's industry-first Human-Centric embodied data engine paradigm — a technical approach that is approximately six months ahead of Tesla's Optimus.
Wenchao Ding, Chief Scientist at Tashi Zhihang, said: "The release of the Tashi WIYH Dataset marks the industry's first large-scale, cross-industry, cross-task collection of vision, language, tactile, and action multimodal data in the real world, laying the foundation for achieving the Scaling Law of embodied foundation models in the future."
The introduction of the Tashi WIYH Dataset signals the formal establishment of a human-centric embodied data paradigm. It makes possible the pre-training of embodied AI World Engines oriented toward the real world. Anchored in "a thousand industries and ten thousand trades," the Tashi WIYH Dataset is expected to realize "one model, a thousand tasks," becoming critical training corpora and infrastructure for general-purpose embodied foundation models and driving industry applications from single-task operations toward a new stage of general manipulation capabilities — laying solid groundwork for embodied robots to truly enter thousands of enterprises and millions of households.
04/
Galaxy Universal's Embodied Large-Model Robot Galbot Debuts at the 2025 China Open
During the 2025 China Open, Qiming Venture Partners portfolio company Galaxy Universal brought its Galaxy Space Capsule to the tournament, injecting fresh technological energy into the event and demonstrating a new paradigm of sports-tech integration through real-world applications.
Deeply committed to the "AI+" strategy, Galaxy Universal has developed the world's first humanoid robot-powered smart retail solution tailored for urban life — the Galaxy Space Capsule. It has already been deployed at renowned scenic spots such as Beijing's Summer Palace and Hangzhou's West Lake, urban communities like Beiwei Community, and core commercial districts including Zhongguancun Darong City and Beijing's Wangfujing, creating multi-scenario demonstration effects across culture and tourism, community, and commercial hub settings.
Each Space Capsule requires as little as 9 square meters of floor space and is autonomously operated by Galaxy Universal's embodied large-model robot Galbot, selling high-frequency consumer goods including beverages, snacks, cultural and creative products, and pharmaceuticals, with compatibility for refrigerated and frozen items. The Space Capsule can increase foot traffic in surrounding areas by 30-40%, effectively activating regional vitality. The embodied large-model robot Galbot handles voice reception, order placement and payment, precise grasping, and product delivery, offering visitors an immersive, interactive smart consumption experience.
05/
Guiwu Smart Debuts DeepWay Intelligent New Energy Heavy Trucks at the 22nd China-ASEAN Expo Smart Equipment Exhibition
Recently, Guiwu Smart Company showcased intelligent new energy heavy trucks from Qiming Venture Partners portfolio company DeepWay at the 22nd China-ASEAN Expo Smart Equipment Exhibition, highlighting their leading intelligent technology and green, efficient transport performance.
DeepWay also jointly showcased a series of intelligent solutions including an autonomous driving logistics collaborative management platform, intelligent platooning transport system, and new energy heavy truck smart logistics management system, attracting visitors to learn about and simulate experiences with the technology.
06/
HyperStrong Supports GWh-Scale Independent Energy Storage Station in Jiuquan, Gansu
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) announced its support for a 250MW/1000MWh independent energy storage station in Jiuquan, Gansu. This is not only the largest single-unit energy storage station currently in grid-connected operation in Gansu, but also demonstrates HyperStrong's full-chain service capabilities from product R&D to station operation and trading.
The project adopts HyperStrong's advanced 5MWh liquid-cooled energy storage system, which through highly integrated design of battery clusters, thermal management, fire protection, and control systems, effectively reduces land occupation and lowers on-site installation complexity, laying a solid foundation for rapid delivery of subsequent projects.
07/
Peking Union Medical College Hospital Showcases AI Medical Product Applications in Collaboration with Left Medical Technology at the Inaugural Medical Artificial Intelligence Conference
At the inaugural Medical Artificial Intelligence Conference (MAIC), Peking Union Medical College Hospital showcased AI medical product applications developed in collaboration with Qiming Venture Partners portfolio company Left Medical Technology. Peking Union Medical College Hospital has fully deployed four core products from Left Medical Technology: AI precision triage, AI precision appointment scheduling, intelligent pre-consultation, and a medical interpretation robot, building an intelligent service system that covers the full patient journey.
Left Medical Technology's AI precision triage deeply integrates natural language understanding technology with medical knowledge graphs, enabling precise disease scope identification through brief patient descriptions and intelligent recommendations of departments, doctors, and relevant medical information. The AI precision appointment scheduling system achieves precise doctor-patient matching and efficient utilization of appointment slots through doctor-specific patient profiling and intelligent questionnaires. The intelligent pre-consultation system effectively addresses two major pain points: underutilization of pre-consultation time and time-consuming electronic medical record documentation. The medical interpretation robot intelligently listens during doctor-patient communication, structurally comprehends key points, and automatically generates standardized medical records for physician review after the consultation, reducing documentation burden while improving clinical quality.
08/
Shenzhen Hongji Medical Debuts at the 14th International Alliance of Urology Annual Congress
Recently, Qiming Venture Partners portfolio company Shenzhen Hongji Medical showcased its urology products at the 14th International Alliance of Urology (IAU) Annual Congress.
During the conference, Professor Olivier Traxer delivered a presentation titled "Because Smaller is Better." He noted that miniaturization of endourological instruments has become a clear clinical trend. Professor Traxer highlighted the real-world surgical performance of Shenzhen Hongji Medical's 6.3Fr flexible ureteroscope: the product achieves a balance between a 6.3Fr outer diameter and 3.6Fr inner diameter, delivering excellent bending maneuverability while significantly reducing the size burden for ureteral access, minimizing potential mucosal damage, improving passage rates, and reducing dilation requirements. In routine clinical practice, its specifications can accommodate over 98% of common cases.
Corporate Honors
Eight Qiming Venture Partners Portfolio Companies Named to China Innovative Drug Decade Glory List
Recently, the China Innovative Drug Decade Glory List was unveiled. The list comprises eight award categories including industry-leading investment institutions, industry-leading CRO companies, industry-leading biotech companies, and industry-leading innovative drugs. Based on comprehensive data from the PharmCube innovative drug industry chain, the selection aims to recognize outstanding institutions, enterprises, and major innovative achievements that have delivered excellent performance over the past decade while playing a significant leading and driving role in the upgrade of China's innovative drug industry — establishing benchmarks for the next decade of China's innovative drug industry. Eight Qiming Venture Partners portfolio companies were named to the list.
On the enterprise list, Qiming Venture Partners portfolio companies Tigermed (300347.SZ, 03347.HK), Frontage Laboratories, and Crown Bioscience were named to the Industry-Leading CRO Companies list; Zai Lab (NASDAQ:ZLAB, 09688.HK), MediLink Therapeutics, Abbisko Therapeutics (02256.HK), Insilico Medicine, and Jacobio Pharmaceuticals (01167.HK) were named to the Industry-Leading Biotech Companies list; and Gleciras, a KRAS G12C inhibitor independently developed by Jacobio (generic name: glecirasib), was named to the Industry-Leading Innovative Drugs list.
Past Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 35, 2025 Qiming Stars | WeRide Enters Ras Al Khaimah, UAE; Robotaxi and Robobus Begin Trial Operations
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.